Gruppo Oncologico del Nord-Ovest
- Country
- 🇮🇹Italy
- Ownership
- Private
- Established
- 1987-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://gonogroup.org/
Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherapy in Patients With Advanced Pancreatic Cancer.
- Conditions
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Interventions
- Drug: 5-FU (5-fluorouracil)
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 340
- Registration Number
- NCT06897644
- Locations
- 🇮🇹
Centro Di Riferimento Oncologico Di Aviano, Aviano, Italy
🇮🇹University Hospital Consorziale Policlinico, Bari, Italy
🇮🇹Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia, Brescia, Italy
Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, As First-line Treatment for Recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients with a PD-L1 Combined Positive Score (CPS)≥1≤19.
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)Recurrent Head and Neck CancerMetastatic Head and Neck Cancer
- Interventions
- Drug: Cetuximab/avelumab
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 67
- Registration Number
- NCT06869473
- Locations
- 🇮🇹
Irccs Humanitas Research Hospital, Rozzano, Milano, Italy
🇮🇹Ospedale Oncologico "A. Businco" ARNAS BROTSU, Cagliari, Italy
🇮🇹Azienda Ospedaliero-Universitaria Policlinico "G. Rodolico-S. Marco, Catania, Italy
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 238
- Registration Number
- NCT06733038
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Luigi Vanvitelli, Naples, Italy
🇮🇹Azienda Ospedaliero Universitaria Policlinico Rodolico - S. Marco, Catania, CT, Italy
🇮🇹Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, FC, Italy
Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 16
- Registration Number
- NCT06578559
- Locations
- 🇮🇹
L'Azienda Ospedaliero Universitaria di Cagliari, Monserrato, CA, Italy
🇮🇹Istituto Romagnolo Per Lo Studio Dei Tumori "Dino Amadori" Irccs Irst, Meldola, FC, Italy
🇮🇹Fondazione Casa Sollievo Della Sofferenza - Irccs, San Giovanni Rotondo, FG, Italy
Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Procedure: 166Holmium TARE
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06332079
- Locations
- 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
- Conditions
- Gastric CancerHER2-positive Gastric Cancer
- Interventions
- Drug: ExperimentalDrug: Control
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 46
- Registration Number
- NCT06253650
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Conditions
- Biliary Tract CancerCholangiocarcinoma
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 300
- Registration Number
- NCT06037980
- Locations
- 🇮🇹
Humanitas Cancer Center, Milan, Italy
🇮🇹Azienda Ospedaliera Universitaria Pisa, Pisa, Italy
🇮🇹ASST Spedali Civili, Brescia, Italy
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
- Conditions
- Colorectal CancerResectable Colorectal Carcinoma
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 112
- Registration Number
- NCT05845450
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Lombardia/MI, Italy
NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 124
- Registration Number
- NCT05802290
- Locations
- 🇮🇹
IRCCS Ospedale San Raffaele, Milano, Italy
🇮🇹Ospedale Papa Giovanni XXIII, Bergamo, Italy
🇮🇹Ospedale Bellaria, Bologna, Italy
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery
- Conditions
- Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Gruppo Oncologico del Nord-Ovest
- Target Recruit Count
- 36
- Registration Number
- NCT05594290
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy